SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is trending following its record-breaking U.S. listing as an ADR, with community discussion centered on whether the debut represents a high-value opportunity in the AI memory space or an overvalued IPO. Traders are actively debating the stock's premium compared to its Korean listing and speculating on how this capital inflow will impact other semiconductor names like Micron and SanDisk.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as market sentiment shifts following a high-profile IPO in the memory sector and ongoing discussions about AI-driven supply constraints. Community sentiment remains polarized, with many investors debating whether the stock is undervalued given its role in the AI infrastructure supercycle or if it is approaching a cyclical peak.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing intense downward pressure driven by an aggressive unwind of leveraged positions in South Korean semiconductor giants, following regulatory concerns over high-leverage ETFs and rebalancing by the National Pension Service. While investors are debating whether this is a temporary technical flush or a more prolonged correction, the community remains divided between those viewing the steep decline as a high-risk buying opportunity and those cautioning against catching a falling knife.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors weigh its long-term potential in direct-to-device satellite connectivity against short-term volatility and sector-wide weakness. Community sentiment is deeply divided, with bulls highlighting upcoming satellite launches and major carrier partnerships as primary catalysts, while vocal short sellers point to liquidity concerns and aggressive competition in the space sector.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the subject of intense community debate as investors weigh the company's strong operational execution, including recent Space Force mission successes, against ongoing volatility driven by sector-wide sympathy selling and insider share sales. Shareholders remain divided between long-term bullish sentiment regarding the Neutron rocket and space infrastructure buildout, and concerns over near-term downward price pressure and institutional liquidity trends.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is currently a focal point for investors as intense market volatility driven by regional geopolitical tensions and semiconductor sector rebalancing captures community attention. Traders are actively debating the sustainability of the AI-driven memory chip trade, with many closely monitoring how aggressive leverage and shifting capital flows into newer, memory-focused ETFs impact the performance of this long-standing South Korea proxy.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently trending as investors debate the impact of its strategic manufacturing joint venture with Toyota, which aims to accelerate the production of its eVTOL aircraft. While the community remains polarized between those focused on long-term growth and commercialization milestones and those concerned by short-term volatility and heavy short interest, many are actively tracking certification progress and the company's ability to scale operations in major markets.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending due to intensifying buyout speculation as investors anticipate a major oncology acquisition to mitigate an upcoming Keytruda patent cliff. Community discussions are centered on potential high-valuation targets within the oncology pipeline, with active debates concerning the likelihood of a strategic acquisition versus organic internal development.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is experiencing high volatility as investors navigate a broader semiconductor sell-off, with the community closely tracking the upcoming U.S. Nasdaq debut of SK Hynix. Traders are actively debating whether this pullback represents an attractive buying opportunity for long-term AI memory exposure or a potential 'sell-the-news' risk as institutional capital rebalances across the sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending due to institutional investors aggressively accumulating long-dated call options, signaling long-term bullish sentiment despite recent volatility and production headwinds. Community discussion remains polarized, focusing on the company's shift toward high-performance battery storage for AI data centers and the upcoming reveal of a new low-cost EV platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MRK 🚨 MUST buy$SLS NOW   $MRK  had billions lined up for $RVMD , but RVMD passed. Now the clock is ticking on the Keytruda patent cliff. Keytruda brings in $30 B a year. When that goes generic, Merck’s revenue falls off a cliff. They need a massive replacement NOW.  
If $SLS falls into the hands of $LLY, $JNJ, or$PFE, Merck loses their oncology crown. Why? Because rivals would lock down the ultimate WT1 platform covering 20+ cancers.  
 
Even worse, the buyer can just use a generic Keytruda with GPS to create an unstoppable super-combo, completely shutting Merck out of the market!  
 
We ALREADY know the GPS + Keytruda combo is a powerhouse—just look at the survival rates in the advanced Ovarian cancer trials! Buy $SLS for $30B now, and it brings in $300B over the next 10 years.  
 
That’s the kind of math that makes a CEO look like an absolute brainiac.  Big pharma  threw $6 BILLION at a FAILED AML drug.  That puts the absolute floor at $25/share right NOW. The math is undeniable. Pay up $MRK

Gediminas Karalius

Tom Wilburn

Sihttegroftnod

Steve B

AkBearHunter

Ludo

Wuzzyup

Steve D

Gray Wolf

Nuutti

Zyntax

Juhana Tikkanen

semihound

10xorbust

Tony M

Polsky007

bikechain

Dew' Moore

Cam Owens

Luke French

G money

Jeff

MoonRiderSLS

Stone Cold Steve Austin

Shawn

Jason

Charles ford

StockTwits Web

Revolution Medicines Inc

SELLAS Life Sciences Group Inc

Lilly(Eli) & Co

Johnson & Johnson

 , but RVMD passed. Now the clock is ticking on the Keytruda patent cliff. Keytruda brings in $30 B a year. When that goes generic, Merck’s revenue falls off a cliff. They need a massive replacement NOW.  
If 

, or$PFE, Merck loses their oncology crown. Why? Because rivals would lock down the ultimate WT1 platform covering 20+ cancers.  
 
Even worse, the buyer can just use a generic Keytruda with GPS to create an unstoppable super-combo, completely shutting Merck out of the market!  
 
We ALREADY know the GPS + Keytruda combo is a powerhouse—just look at the survival rates in the advanced Ovarian cancer trials! Buy 

 for $30B now, and it brings in $300B over the next 10 years.  
 
That’s the kind of math that makes a CEO look like an absolute brainiac.  Big pharma  threw $6 BILLION at a FAILED AML drug.  That puts the absolute floor at $25/share right NOW. The math is undeniable. Pay up 

@dewmoore Merck definitely has an issue.   While Keytruda has been great is a two sided knife in regards to the percentage of total revenue it is for them.   About 50% of their total revenue is Keytruda and that is devastating when faced with this situation.  The beauty about the SLS platforms is they don&#39;t just solve Merck&#39;s issues,  they allow them continued growth with the maintenance program they&#39;ll be administered under.   Merck would go from losing half their revenue to further separating themselves from the pack in oncology innovation.

Nevertheless, this going to be fun to watch it unfold over the next few months.... maybe even weeks!

cheetohottaki

george Qi

mrittika1971

StockTwits For Android 

 Merck definitely has an issue.   While Keytruda has been great is a two sided knife in regards to the percentage of total revenue it is for them.   About 50% of their total revenue is Keytruda and that is devastating when faced with this situation.  The beauty about the SLS platforms is they don't just solve Merck's issues,  they allow them continued growth with the maintenance program they'll be administered under.   Merck would go from losing half their revenue to further separating themselves from the pack in oncology innovation.

Nevertheless, this going to be fun to watch it unfold over the next few months.... maybe even weeks!

StockTwits for iOS

@dewmoore it won&#39;t they have a subcontaeous version which is faster and can be done anywhere. They said this about Abbvie patent cliff too. It will hold better than anticipated

 it won't they have a subcontaeous version which is faster and can be done anywhere. They said this about Abbvie patent cliff too. It will hold better than anticipated

TeDeVan

@dewmoore Ibrx drug ANKTIVA  with Keytruda combo is much better then Keytruda alone or any other combo. GO LOOK

 Ibrx drug ANKTIVA  with Keytruda combo is much better then Keytruda alone or any other combo. GO LOOK